AIDS 2026

AIDS 2026
July 26-31, 2026
Rio de Janeiro, Brazil

International AIDS Conference 2026 .

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (24)

    Modeling Strategies to Maximize PrEP Impact in the United States with Twice-Yearly Lenacapavir

    • Author(s): Moore, M
    • yeztugo
    • HIV / AIDS

    Genotypic data from participants screened for the PURPOSE 1 and PURPOSE 2 studies demonstrate low level of overall circulating resistance and no phenotypic resistance to lenacapavir

    • Author(s): Cox, S
    • yeztugo
    • HIV / AIDS

    Increased treatment satisfaction and maintained high health-related quality of life among people with HIV switching to a bictegravir/lenacapavir single-tablet regimen from complex regimens: Results from the Phase 3 ARTISTRY-1 trial

    • Author(s): Orkin, C
    • bic/len
    • HIV / AIDS

    Resistance Profile of the HIV Integrase Strand Transfer Inhibitor GS-3242, a Potent Novel Long-Acting Injectable INSTI in Clinical Development

    • Author(s): Hansen, D
    • gs-3242
    • HIV / AIDS

    Endorsement and anticipated challenges to adopting twice-yearly lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP) among cisgender men who have sex with men (MSM): Qualitative insights from the PURPOSE 2 trial

    • Author(s): Meanley, S
    • yeztugo
    • HIV / AIDS

    Integrating gender-affirming hormone therapy with twice-yearly subcutaneous lenacapavir for HIV prevention: Longitudinal qualitative insights from transgender and nonbinary PURPOSE 2 participants

    • Author(s): Meanley, S
    • yeztugo
    • HIV / AIDS

    Experiences with twice-yearly lenacapavir for PrEP in the PURPOSE 1 open-label extension phase

    • Author(s): Nkosi, T
    • yeztugo
    • HIV / AIDS

    Optimizing STI Testing Frequency Among PrEP Users: Implications for Long-Acting HIV Prevention in the Real-world Setting

    • Author(s): Tao, L
    • yeztugo
    • HIV / AIDS

    Favorable Tolerability of Lenacapavir for PrEP Administered at Participant-Chosen Anatomic Sites in PURPOSE 1 and PURPOSE 2

    • Author(s): Brites, C
    • yeztugo
    • HIV / AIDS

    Efficacy and safety of BIC/LEN single-tablet regimen in virologically suppressed people with HIV aged ≥65 Years: Week 48 analysis of participants in the Phase 3 portion of ARTISTRY-1

    • Author(s): Bloch, M
    • bic/len
    • HIV / AIDS

    Pharmacokinetic data supporting the safety and efficacy of BIC/LEN in Phase 3 studies

    • Author(s): Arora, P
    • bic/len
    • HIV / AIDS

    Efficacy and safety of single-tablet BIC/LEN compared with B/F/TAF in maintaining virologic suppression across age, sex, race, and geographic region subgroups in ARTISTRY-2

    • Author(s): Cahn, P
    • biktarvy
    • bic/len
    • HIV / AIDS

    Metabolic changes at 48 weeks in people with HIV and virologic suppression switching to single-tablet bictegravir/lenacapavir from complex antiretroviral regimens: Results from the Phase 3 ARTISTRY-1 trial

    • Author(s): Cassetti, I
    • bic/len
    • HIV / AIDS

    Immune Biomarker Characterization of Amtabafusp (ABF), a Bispecific T-cell Engager, in a Phase 1b study in People with HIV

    • Author(s): Zhang, L
    • amtabafusp
    • HIV / AIDS

    Baseline and Week 48 Resistance Analyses in the Phase 3 ARTISTRY-1 Study Evaluating the Bictegravir/Lenacapavir Single-Tablet Regimen

    • Author(s): Margot, N
    • bic/len
    • HIV / AIDS

    High Efficacy of Twice-Yearly Subcutaneous Lenacapavir for PrEP Through 52 Weeks of Open-Label Extension in PURPOSE 2

    • Author(s): Losso, M
    • yeztugo
    • HIV / AIDS

    Efficacy and Safety of Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab as an HIV-1 Treatment Up to 104 Weeks

    • Author(s): McMahon, J
    • len + tab + zab
    • HIV / AIDS

    Long-term safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve adolescents and virologically suppressed children with HIV-1

    • Author(s): Rakhmanina, N
    • genvoya
    • HIV / AIDS

    Low incidence of treatment-emergent resistance to bictegravir/emtricitabine/tenofovir alafenamide under real-world adherence conditions among people with HIV in the United States, 2018-2024

    • Author(s): Levintow, S
    • biktarvy
    • HIV / AIDS

    Outcomes in treatment-experienced (TE) people with HIV (PWH) and detectable viremia switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice: 24-month (M) results from the BICSTaR study

    • Author(s): Welzen, B
    • biktarvy
    • HIV / AIDS

    Once-weekly oral islatravir/lenacapavir (ISL/LEN) versus daily standard-of-care therapy in virologically suppressed adults with HIV-1: Week 48 results of the ISLEND-2 Phase 3 trial

    • Author(s): Colson, A
    • isl/len
    • HIV / AIDS

    Zero HIV infections with twice-yearly subcutaneous lenacapavir for PrEP during 52 weeks of open-label extension in PURPOSE 1

    • Author(s): Kiwanuka, N
    • yeztugo
    • HIV / AIDS

    Once-weekly oral islatravir/lenacapavir (ISL/LEN) versus daily bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with HIV-1: Week 48 results of the ISLEND-1 Phase 3 trial

    • Author(s): Rockstroh, J
    • isl/len
    • biktarvy
    • HIV / AIDS

    Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in children and adolescents with HIV-1 aged 2 to <18 years

    • Author(s): Natukunda, E
    • biktarvy
    • HIV / AIDS